YHIEPV (CAS No. 2243939-21-9) – Orally Active Peptide for Anxiolytic and Anti-Obesity Research

描述

YHIEPV (rALP-2, Rubisco anxiolytic-like peptide 2) is an innovative peptide designed for research into anxiety disorders and obesity. This peptide demonstrates both anxiolytic activity and the ability to increase leptin sensitivity, which makes it a promising tool for exploring novel interventions in metabolic and neurological disorders.

The peptide is orally active, providing researchers with a convenient mode of administration in laboratory studies, including murine and other preclinical models. Its chemical stability and precise synthesis allow consistent dosing and reproducible experimental results, critical for translational research.

In anxiety research, YHIEPV has shown significant modulation of neurobehavioral responses. Preclinical studies indicate that YHIEPV can reduce markers of stress-related behavior, including elevated plus maze and open field tests. These anxiolytic effects are thought to involve modulation of central neurotransmitter pathways, although the detailed mechanisms are still being elucidated in laboratory settings.

In addition to neurological effects, YHIEPV has been observed to enhance leptin sensitivity. Leptin, a hormone central to energy homeostasis and appetite regulation, often becomes dysregulated in obesity. By increasing leptin sensitivity, YHIEPV promotes satiety signaling and energy balance, making it a valuable research tool for metabolic studies. This dual activity—anxiolytic and anti-obesity—provides unique opportunities to study the interplay between stress, neuroendocrine regulation, and metabolic disorders.

Produced under strict GMP conditions, YHIEPV is supplied with high purity and minimal batch-to-batch variation. This ensures reliability for both small-scale laboratory experiments and larger preclinical studies. The peptide is lyophilized for long-term storage and can be reconstituted in suitable solvents for experimental use.

Researchers have employed YHIEPV in in vitro studies to assess neuronal and hypothalamic cell responses, while in vivo models focus on behavioral assays, appetite regulation, and body weight management. YHIEPV’s synthetic origin allows for precise structural modification, enabling further exploration of structure-activity relationships and optimization of pharmacological effects.

Its oral activity is particularly advantageous in obesity research, where repeated injections can be stressful to animal models and potentially confound metabolic studies. The peptide’s stability and bioavailability make it a reliable candidate for chronic administration in experimental protocols.

Overall, YHIEPV offers researchers a highly versatile tool to investigate both anxiolytic mechanisms and metabolic regulation. Its dual functionality has the potential to yield insights into the connections between stress, appetite, and obesity, and may inspire the development of future therapeutic approaches.

Strictly for laboratory research use, YHIEPV is not approved for human use, therapeutic application, or clinical diagnostics. All experimental work should be conducted in controlled laboratory environments by trained personnel.

Product Specifications

The high-purity GMP-compliant peptide ensures reproducibility and reliability for both in vitro and in vivo studies. Laboratory researchers should handle YHIEPV with appropriate safety protocols, including personal protective equipment and controlled storage.

Mechanism of Action & Research Applications

YHIEPV exerts its effects through a multifaceted mechanism of action. Its anxiolytic properties are believed to involve modulation of neurotransmitter systems within the central nervous system. Experimental evidence suggests interactions with GABAergic and glutamatergic signaling pathways, which play a critical role in stress and anxiety modulation. In preclinical behavioral studies, YHIEPV administration reduces anxiety-like behavior, stabilizes exploratory activity, and mitigates stress-induced physiological responses.

The anti-obesity effects of YHIEPV are mediated by enhancement of leptin sensitivity. Leptin, produced primarily in adipose tissue, regulates food intake and energy expenditure through hypothalamic signaling. In obesity, leptin resistance often impairs this feedback loop, leading to increased appetite and weight gain. By sensitizing leptin receptors, YHIEPV restores proper signaling, promoting satiety, energy expenditure, and improved metabolic homeostasis.

In vitro studies have shown that YHIEPV modulates cellular responses in hypothalamic neurons, improving leptin receptor signaling and reducing markers of leptin resistance. In vivo models demonstrate decreased food intake, reduction in body weight, and improvements in lipid metabolism, highlighting the peptide’s translational potential in metabolic research.

YHIEPV is a valuable research tool for exploring the interactions between stress and metabolic regulation. Chronic stress often disrupts hormonal balance, promoting hyperphagia and weight gain. The dual anxiolytic and anti-obesity actions of YHIEPV allow researchers to investigate how stress-modulated neural circuits influence metabolic disorders, providing insight into potential therapeutic targets.

Additionally, YHIEPV’s oral bioavailability supports chronic administration in rodent models, enabling longitudinal studies on behavioral and metabolic outcomes without confounding injection-related stress. Its chemical stability and GMP-compliant production ensure reliable results across experiments.

Beyond anxiety and obesity research, YHIEPV may be useful for studying metabolic syndrome, type 2 diabetes, and neuroendocrine regulation. Investigators can explore its effects on appetite-regulating hormones, inflammatory cytokines, and central nervous system plasticity.

Side Effects

While YHIEPV is intended strictly for laboratory research, preclinical studies provide insight into potential biological effects. In experimental models, mild gastrointestinal disturbances or transient behavioral changes may occur at higher doses. These effects are generally reversible and dose-dependent.

Due to its potent modulation of central and metabolic pathways, YHIEPV could theoretically influence off-target neurotransmitter signaling, highlighting the importance of controlled dosing in laboratory experiments. Researchers should carefully monitor physiological and behavioral responses in in vivo studies.

YHIEPV’s synthetic nature ensures low immunogenicity in preclinical models, yet proper experimental controls remain essential to distinguish genuine pharmacological effects from experimental artifacts. Handling precautions, such as PPE, controlled storage, and proper waste disposal, are recommended to minimize exposure risks.

It is important to emphasize that YHIEPV is not approved for clinical or therapeutic use, and all side effect observations are strictly within laboratory contexts. Researchers should design studies following institutional safety and ethical guidelines.

Disclaimer

 (CAS No. 2243939-21-9) is provided for laboratory research use only. It is not intended for human consumption, therapeutic use, or diagnostic purposes. All experimental work must be conducted by qualified personnel in controlled laboratory environments.

Keywords

• rALP-2 peptide

• CAS 2243939-21-9

• anxiolytic peptide research

• anti-obesity peptide

• leptin sensitivity enhancer

• GMP YHIEPV supplier

• orally active peptide

• neurobehavioral research peptide